Baicalein for Parkinson's Disease
Also known as: 5,6,7-Trihydroxyflavone, Scutellaria baicalensis extract
Baicalein directly inhibits α-synuclein aggregation — the central pathological protein in Parkinson's disease.
Mechanism of Action
Baicalein binds α-synuclein monomers and prevents their assembly into toxic oligomers and fibrils. It inhibits 12/15-lipoxygenase (reducing neuroinflammation), activates Nrf2, and protects dopaminergic neurons through multi-target neuroprotection.
General mechanism: Flavone from Scutellaria. 12/15-LOX inhibitor, α-synuclein aggregation inhibitor, ferroptosis modulator, Nrf2 activator.
Current Evidence
Extensive preclinical evidence for α-synuclein inhibition. Direct binding confirmed by NMR studies. Dopaminergic neuroprotection in MPTP and rotenone models. No PD clinical trials.
Clinical Status: Preclinical. Strong mechanistic rationale for PD.
Safety Profile
Safe. Traditional medicine use. GI effects possible. May interact with iron metabolism at high doses.
Key Research Questions
- Can baicalein reduce α-synuclein aggregation in PD patients?
- What baicalein dose achieves α-synuclein-inhibiting concentrations in brain?